Helzert, K. T.; Sharifi, M. N.; Spergert, J. M.; Shi, Y.; Annala, M.; Bootsma, M. L.; Reese, S. R.; Taylor, A.; Kaufmann, K. R.; Krause, H. K.; Schehr, J. L.; Sethakorn, N.; Kosoff, D.; Kyriakopoulos, C.; Burkard, M. E.; Rydzewski, N. R.; Yu, M.; Harari, P. M.; Bassetti, M.; Blitzer, G.; Floberg, J.; Sjoestroem, M.; Quigley, D. A.; Dehm, S. M.; Armstrong, A. J.; Mckay, R. R.; Beltran, H.; Feng, F. Y.; O'Regan, R.; Wisinski, K. B.; Emamekhoo, H.; Wyatt, A. W.; Lang, J. M.; Zhao, S. G.

A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm

HER2-low乳腺癌治疗方案综述及治疗排序算法

CANCER

IF5.1

2023-06-226

OAAI

Margetuximab in HER2-positive metastatic breast cancer

FUTURE ONCOLOGY

IF2.6

2023-05-126

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer

使用Oncotype DX乳房复发评分®新辅助内分泌治疗在早期激素受体阳性乳腺癌中的作用

BREAST CANCER RESEARCH AND TREATMENT

IF3

2023-03-106

OAAI

When the personal becomes political: The impact of the Dobbs decision on women with cancer

CANCER

IF5.1

2022-11-072

PRE

Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases

乳腺癌脑和软脑膜转移的系统治疗方法

CURRENT TREATMENT OPTIONS IN ONCOLOGY

IF4.7

2022-09-223

PRE

Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel

染色体不稳定性使患者乳腺肿瘤对紫杉醇诱导的多极分裂敏感

SCIENCE TRANSLATIONAL MEDICINE

IF14.6

2021-09-0876

Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy

NATURE CANCER

IF28.5

2021-06-0338

OAAI

Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive breast cancer: One Monarch to rule them all?

CANCER

IF5.1

2021-05-284

OAAI

Breast Cancer, Version 4.2021 Featured Updates to the NCCN Guidelines

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

IF16.4

2021-05-0160

Gradishar, William J.; Moran, Meena S.; Abraham, Jame; Aft, Rebecca; Agnese, Doreen; Allison, Kimberly H.; Blair, Sarah L.; Burstein, Harold J.; Dang, Chau; Elias, Anthony D.; Giordano, Sharon H.; Goetz, Matthew P.; Goldstein, Lori J.; Hurvitz, Sara A.; Isakoff, Steven J.; Jankowitz, Rachel C.; Javid, Sara H.; Krishnamurthy, Jairam; Leitch, Marilyn; Lyons, Janice; Matro, Jennifer; Mayer, Ingrid A.; Mortimer, Joanne; O'Regan, Ruth M.; Patel, Sameer A.; Pierce, Lori J.; Rugo, Hope S.; Sitapati, Amy; Smith, Karen Lisa; Smith, Mary Lou; Soliman, Hatem; Stringer-Reasor, Erica M.; Telli, Melinda L.; Ward, John H.; Wisinski, Kari B.; Young, Jessica S.; Burns, Jennifer L.; Kumar, Rashmi

EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2-positive (HER2+) advanced breast cancer (ABC)

ANNALS OF ONCOLOGY

IF65.4

2020-09-017

OAAI

Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer

CURRENT TREATMENT OPTIONS IN ONCOLOGY

IF4.7

2020-08-151

PREAI

Ruth O'Regan

个人简介

教育背景

工作经历

荣誉奖项

研究方向